StockMarketWire.com - PureTech Health noted that affiliate company Karuna Therapeutics met its primary goal in a clinical trial of a treatment of acute psychosis in patients with schizophrenia.
The treatment, called, KarXT, demonstrated a statistically significant and clinically meaningful 11.6 point mean reduction in total Positive and Negative Syndrome Scale (PANSS) score compared to placebo.
It also demonstrated good overall tolerability.
A statistically significant reduction in the secondary endpoints of PANSS-Positive and PANSS-Negative scores were also observed.
'These impressive results are another important validation of PureTech's innovation engine that has generated highly differentiated platforms to address serious diseases,' PureTech chief executive Daphne Zohar said.
'It is very exciting to see Karuna reach this important milestone with its lead candidate KarXT that originated at PureTech.'
'KarXT is now being advanced by one of the leading CNS drug development teams and has the potential to be the first novel therapeutic approach in decades to treat psychosis in patients with schizophrenia and Alzheimer's disease.'
At 1:01pm: [LON:PRTC] PureTech Health Plc share price was +3p at 222p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.